Market Cap (In EUR)
2.23 Million
Revenue (In EUR)
-
Net Income (In EUR)
-14.75 Million
Avg. Volume
99.48 Thousand
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0428-2.35
- PE
- -
- EPS
- -
- Beta Value
- 0.342
- ISIN
- CH0308403085
- CUSIP
- H33418106
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Jesus Martin-Garcia
- Employee Count
- -
- Website
- https://www.geneuro.com
- Ipo Date
- 2016-04-15
- Details
- GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
More Stocks
-
VUNVunani Limited
VUN
-
5248
-
LNDAF
-
6731Pixela Corporation
6731
-
SKJESkjern Bank A/S
SKJE
-
HIZOF
-
7018
-
AAEEFAltair Resources Inc.
AAEEF